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ABSTRACT 
 
 Targeting the CD40 receptor displayed by antigen-presenting cells to deliver a 
specific immunogen has been successfully used to enhance immune responses, 
specifically increasing antibody production and enhancing antibody affinity.  When 
tested in chickens, this platform induced specific IgG and IgA production within one 
week post-immunization.  However, proof of conferred protective efficacy using the 
CD40-targeting vaccination method was still undetermined.  Whole avian influenza 
virus was loaded onto the guided complex and immunized birds were challenged with 
highly pathogenic avian influenza (HPAI) to test efficacy.  Furthermore, this research 
addresses the application of guided complexes as an alternative method for epitope 
mapping of microbial enzymes.  Short peptide segments of the Clostridium perfringens 
alpha toxin were loaded onto the antibody-guided complex and immunized into chickens 
to induce antibody production for downstream use in neutralization assays to identify 
specific regions able to block the toxin’s enzymatic functions.  Lastly, to expand the 
antibody-guided system repertoire, monoclonal antibodies against a new receptor, 
specifically dendritic cell (DC) marker CD205, were developed for potential use to 
further enhance immune response activation.  Anti-CD205 monoclonal antibodies were 
used to develop a new in vitro DC system obtained from peritoneal exudate cells.   
In HPAI efficacy studies, functional antibody titers were detected up to six weeks 
after a single subcutaneous administration.  When boosted, the antibody-guided complex 
conferred 100% protection in birds upon lethal H5N1 challenge.  The guided system also 
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proved useful for rapid polyclonal antibody production in chickens, which can be used in 
epitope mapping studies.  This system favors linear peptide targets for immunization in 
order to maintain cost-effectiveness and short turnover time, but can still be used with 
conformational epitopes.  Monoclonal antibodies were successfully constructed against 
chicken CD205 and used in a variety of immunoassays, as well as magnetic bead 
isolation of DCs from peritoneal exudate cell populations.  Overall, these data are the 
first to report protective efficacy using the CD40-targeting system in chickens, the first 
to propose the use of guided complexes in epitope mapping, and the first to isolate DCs 
from peritoneal exudate using the anti-CD205 monoclonal antibodies.  
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Ab antibody 
Ad adherent 
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ANOVA analysis of variance 
APC antigen presenting cell 
APHIS Animal and Plant Health Inspection Service 
BSA bovine serum albumin 
cDNA complementary deoxyribonucleic acid 
CLECT C-type lectin binding domain 
Cpa Clostridium perfringens alpha toxin 
DAPI 4',6-diamidino-2-phenylindole 
DC dendritic cell 
DIVA differentiation of infected from vaccinated animals 
DMEM Dulbecco’s modified eagle medium 
EID50 50% embryo infectious dose 
ELISA enzyme-linked immunosorbent assay 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
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Ig immunoglobulin 
IL-4 interleukin 4 
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NetB necrotic enteritis toxin-like beta 
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PAMP pathogen-associated molecular patterns 
PBMC peripheral blood mononuclear cells 
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PCR polymerase chain reaction 
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PRR pattern recognition receptor 
RIG-I retinoic acid inducible gene I 
RPMI Roswell Park Memorial Institute medium 
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TLR toll-like receptor 
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TNF-α tumor necrosis factor alpha 
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USDA United States Department of Agricultur   
 
  x 
TABLE OF CONTENTS 
 Page 
ABSTRACT ....................................................................................................................... ii	
ACKNOWLEDGEMENTS .............................................................................................. iv	
CONTRIBUTORS AND FUNDING SOURCES ............................................................. vi	
NOMENCLATURE ......................................................................................................... vii	
TABLE OF CONTENTS ................................................................................................... x	
LIST OF FIGURES .......................................................................................................... xii	
LIST OF TABLES .......................................................................................................... xiv	
CHAPTER I  INTRODUCTION ....................................................................................... 1	
Brief Introduction to the Poultry Industry ...................................................................... 1	
Diseases and Other Challenges Faced by the Industry .................................................. 1	
Avian Immune System ................................................................................................... 7	
Antibodies in Therapeutic Use ..................................................................................... 13	
Antibody-Guided Complexes ....................................................................................... 15	
CHAPTER II  A FAST AND INEXPENSIVE PROTOCOL FOR EMPIRICAL 
VERIFICATION OF NEUTRALIZING EPITOPES IN MICROBIAL TOXINS AND 
ENZYMES ....................................................................................................................... 19	
Introduction .................................................................................................................. 19	
Materials and Methods ................................................................................................. 21	
Results .......................................................................................................................... 26	
Discussion .................................................................................................................... 30	
CHAPTER III   DELIVERING INACTIVATED AVIAN INFLUENZA TO 
ANTIGEN PRESENTING CELLS BY TARGETING CD40 FOR ENHANCED 
PROTECTION AGAINST LETHAL CHALLENGE ..................................................... 33	
Introduction .................................................................................................................. 33	
Materials and Methods ................................................................................................. 37	
Results .......................................................................................................................... 41	
Discussion .................................................................................................................... 47	
  xi 
CHAPTER IV   DEVELOPMENT OF MONOCLONAL ANTIBODIES AGAINST 
DENDRITIC CELL MARKER CD205 AND ITS USE TO ISOLATE DENDRITIC 
CELLS FROM PERITONEAL EXUDATE CELLS ....................................................... 51	
Introduction .................................................................................................................. 51	
Materials and Methods ................................................................................................. 53	
Results .......................................................................................................................... 58	
Discussion .................................................................................................................... 67	
CHAPTER V  CONCLUSIONS ...................................................................................... 71	
REFERENCES ................................................................................................................. 77	
 
  xii 
LIST OF FIGURES 
 Page 
Figure 1.  Abbas et al.’s diagram of basic steps to B-cell activation and proliferation. .. 11	
Figure 2.  Geijtenbeek et al.’s diagram of dendritic cell presenting antigen on MHC-I 
and MHC-II. ..................................................................................................... 12	
Figure 3.  Schematic of antibody-guided complex loaded with peptide antigen. ............ 17	
Figure 4.  Schematic of 23 peptides generated based on C. perfringens alpha toxin 
amino acid sequence. ........................................................................................ 22	
Figure 5.  Peptide-specific IgG responses. ....................................................................... 27	
Figure 6.  Mean hemolytic neutralization titers. .............................................................. 29	
Figure 7.  Mean phospholipase C neutralization titers. .................................................... 30	
Figure 8.  Antibody-guided adjuvant complex schematic. ............................................... 36	
Figure 9.  Clone C was the most immunogenic of the three candidate anti-M2e 
monoclonal antibodies. ..................................................................................... 43	
Figure 10.  Subcutaneous administration induces the highest immune response. ........... 45	
Figure 11.  Diagram of CD205 domains. ......................................................................... 52	
Figure 12.  Immunofluorescent staining of non-adherent PECs with APC marker 
antibodies. ......................................................................................................... 59	
Figure 13.  Expression of CD205 mRNA in non-adherent PECs but not in adherent 
PECs. ................................................................................................................ 60	
Figure 14.  Truncated CD205 protein expressed in E. coli system based on His-tag 
staining. ............................................................................................................. 61	
Figure 15.  Screening of different candidate monoclonal antibodies against CD205 on 
non-adherent PECs. .......................................................................................... 62	
Figure 16.  Crude vs. CD205+ sorted PECs. ..................................................................... 65	
Figure 17.  Unsorted PECs cultured and LPS-activated/stimulated. ................................ 66	
Figure 18.  PECs sorted for CD205+ cells cultured and activated. .................................. 66	
  xiii 
Figure 19.  Immunofluorescent staining of CD205+ sorted and activated PECs against 
APC markers. .................................................................................................... 67	
Figure 20.  CD205+ sorted spleen cells. ........................................................................... 67	
 
  xiv 
LIST OF TABLES 
 Page 
Table 1.  C. perfringens alpha toxin-derived synthetic peptides. ..................................... 23	
Table 2.  HPAI-loaded adjuvant complex challenge trial treatment groups and 
survival data. ..................................................................................................... 46	
Table 3.  Flow cytometry using anti-CD205 mAb on spleen and PBMC samples. ......... 64	
Table 4.  Magnetic sorting of CD205+ cells. .................................................................... 64	
 
 
 
 
 
  1 
CHAPTER I  
INTRODUCTION 
 
Brief Introduction to the Poultry Industry 
Poultry production is an extensive global industry as birds are less costly to feed, 
require less space, and are quicker to mature than other domesticated animals used for 
meat production. In the US, over 54 billion pounds of broiler meat (1) and over 102 
billion eggs (2) were produced in 2016, as reported by the USDA National Agricultural 
Statistics Service.  As a relatively affordable source of high quality animal protein, more 
poultry has been consumed per capita than any other animal-based protein source (3).  
Due to the large-scale nature of the industry and high stocking density of birds, proper 
care and health management is integral to successful and humane rearing of birds.   
 
Diseases and Other Challenges Faced by the Industry 
Antimicrobial growth promoters (AGPs) were officially approved for use in 
animal feeds in 1951, with 32 antimicrobials available for use without veterinary 
prescription.  Of the original 32 approved compounds, 15 possessed anti-coccidial 
properties and 11 served as growth promoters at sub-therapeutic doses (4).  The exact 
mechanism by which AGPs were able to improve growth is largely unknown, but it has 
been suggested that the use of antimicrobials reduces overall gut inflammation and 
allows for more efficient nutrient absorption (5).  The use of AGPs continued for 
decades until concern over the increase in antibiotic-resistant bacteria prompted the ban 
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of specific AGPs as a feed additive in Denmark, a regulation later implemented by other 
countries in the European Union (6, 7).  Due to rising consumer concern over the use of 
AGPs in livestock, commercial producers in the United States have also limited or 
ceased their usage.  Since the removal of AGPs from feed, increased incidences of 
coccidiosis and necrotic enteritis (NE) have been observed (8, 9).  This is especially true 
with increasing consumer demand for free-range birds, which encounter more pathogens 
than their conventionally housed counterparts.   Although the use of ionophore-based 
coccidiostats has not been banned, some producers have preemptively halted the use of 
these drugs, further increasing the potential threat of coccidiosis in their flocks.  
Numerous alternatives have been tested to replace AGPs, ranging from probiotics to 
novel feed additives, but none have proven as effective as AGPs and none have been 
universally adopted by the industry (10). 
 
Necrotic Enteritis 
Necrotic enteritis is a multifactorial disease affecting poultry, primarily causing 
damage in the gastrointestinal tract, and in severe cases, resulting in mortality rates 
ranging from 2-10% (8).  The essential causative agent of NE is Clostridium perfringens, 
but infection with this bacterium alone does not by itself cause disease.  Clostridium 
perfringens is a Gram-positive anaerobic species that is ubiquitous in soil and is 
normally present at low levels in the bird’s enteric microflora.  Dysbiosis of the gut 
environment, inducing increased mucoid viscosity, triggers the overgrowth of the 
normally low levels of C. perfringens (11).  This imbalance can be caused by many 
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different factors, such as a diet with excess non-starch polysaccharides (barley, wheat, 
rye, etc.) or a preexisting gut infection (coccidiosis, salmonellosis, etc.) (12, 13).  As 
producers are reluctant to use ionophores to control coccidiosis, use of coccidial 
vaccines has become more common.  These vaccines are live-pathogen based and 
purposely designed to induce subclinical natural infection, but their use has been 
reported to inadvertently increase the incidence of NE (14).  Previously, NE disease was 
controlled by the addition of antibiotics such as bacitracin and lincomycin to the feed, 
but efforts to limit the use of antibiotics have essentially removed these options as 
prophylactic tools to prevent the disease. 
Clinical signs of NE include a sudden onset of depression, diarrhea, and 
potentially death.  Upon necropsy, lesions can be observed in the small intestine and is 
the typical method of diagnosis by attending veterinarians, but definitive laboratory 
diagnosis requires histological staining or culture of the lesions for C. perfringens.  The 
actual damage is not caused by replication of the bacteria itself, but by the resulting 
release of a cocktail of toxins, inducing an enterotoxemia (15).  Clostridium perfringens 
toxins are mainly categorized as either alpha, beta, epsilon, or lambda; in addition, each 
major toxin class is micro-heterogeneous and consists of a number of toxin-like variants 
(16).  In poultry, the primary cause of NE-induced intestinal damage primarily originates 
from the hemolytic and phospholipase C enzymatic activities of alpha toxin (17).  
Various attempts have been made to design vaccines against NE by targeting alpha 
toxin, but most of those candidate vaccines have only provided partial protection or have 
not been formulated for use in poultry.  Immunogens tested include whole recombinant 
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toxin, partial recombinant toxin, short peptide regions of the toxin, subunits of toxin 
expressed in vectors, and whole toxin expressed in bacterial vectors (18-21).  Despite the 
many attempts at vaccine formulation and improved knowledge of the domains required 
for enzymatic function, a specific epitope region that provides complete protection 
against the disease has yet to be recognized by the scientific community (22).  More 
recently, data have stated that alpha toxin may be non-essential (23) and a necrotic 
enteritis toxin-like beta variant (NetB) was asserted to be the main cause of disease (24), 
but initial studies solely targeting NetB as a vaccine candidate have proven unsuccessful 
(25) and further sequencing of virulent C. perfringens strains revealed that many did not 
possess the NetB gene.  Despite this lead, alpha toxin seems to remain to be the primary 
culprit of NE-associated morbidity.  Some further attempts have been made to identify 
protective epitopes on the toxin, but this work has mainly relied on time-consuming, 
laborious site-directed mutagenesis and protein expression techniques (22, 26-28).  
Development of a new more cost-effective method for epitope mapping would not only 
be beneficial for the study of alpha toxin, but also for mapping other enzymes. 
 
Avian Influenza 
Another disease of economical importance to the poultry industry would be avian 
influenza (AI).  Avian influenza virus (AIV) is a member of the Orthomyxoviridae virus 
family, possessing a segmented, negative-sense RNA genome capable of infecting both 
avian and mammalian hosts.  Influenza viruses are classified by their hemagglutinin 
(HA) and neuraminidase (NA) proteins, which required for attachment and release of the 
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virion from the host cell (29).   Due to the fact that both proteins are highly expressed on 
the surface of the virus, host antibody responses are primarily directed towards these 
external proteins.  Protection against disease has been correlated to high circulating 
antibody titers against the HA protein, preventing initial attachment of the virus to the 
host cell and therefore preventing infection of host cells, and hence viral replication and 
establishment of disease symptoms.  Although vaccines have been developed against 
AIV, efficacy issues arise due to lack of cross-protection against different AIV subtypes.  
There are 16 distinct antigenic HA subtypes (H1-H16) and possessing neutralizing 
antibodies against one subtype does not guarantee protection against another subtype.   
Small mutations commonly occur in AIV, as this virus possesses a RNA genome 
and is more prone to error during normal replication events (30).  These small mutations 
accumulate over time as the virus spreads from one population to the next and is referred 
to as antigenic drift (30).  The accumulated mutations from one flu season to the next as 
the virus circulates around the globe is the main cause and requirement for annual flu 
vaccine reformulations in humans, as each year’s formulation must be updated to the 
major circulating strain.  Periodic strain updates occur in poultry vaccines against AI, as 
needed.  Large genome mutations can also occur suddenly when two or more viruses 
infect the same cell and exchange genome segments during replication, which is referred 
to as antigenic shift.  These larger, abrupt changes can result in pandemic outbreaks 
since the existing host populations do not possess any level of immunity against this 
newly produced virus, as was the case in the 2003 and 2009 H5N1 pandemics (31).   
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Highly pathogenic avian influenza (HPAI) is capable of inducing 75-100% 
mortality in birds within 4 days of infection, while low pathogenic avian influenza 
(LPAI) may cause mild respiratory issues and general lethargy, or even no symptoms at 
all.  Though highly pathogenic strains can result from antigenic shift, a major disease 
threat can also result from the small mutations accumulated during antigenic drift.  HA 
protein cleavage required for successful attachment and invasion of host cells by the 
virus is typically achieved by exogenous trypsin from the host’s respiratory and 
gastrointestinal tract (32).  If this cleavage site were altered to a polybasic sequence, this 
crucial cleavage could be performed by furin-like proteases ubiquitously expressed in 
the body, allowing the viral infection to become systemic and no longer limited to the 
respiratory or gastrointestinal tracts (32). 
Avian influenza is a disease that, although not endemic to the United States, is 
becoming more of a threat.  Outbreaks of HPAI have occurred within the United States, 
with disease and control efforts that resulted in the death of over 48 million poultry in 
the 2014-2015 outbreak and 400,000 poultry in the 2016 Indiana outbreak (33), both of 
which resulted in large economic losses and reduced food production in the country.  
The United States does not actively vaccinate against this disease as this would cause 
issues with differentiating infected from vaccinated animals (DIVA) and therefore 
interfere with the country’s international trading status as an AI-free country (34).  
Outbreaks of AI immediately trigger a “stamping out” approach in which entire flocks of 
affected birds are killed and the corresponding housing and equipment vigorously 
disinfected (35).  Despite these efforts, HPAI outbreaks still randomly occur within this 
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country.  Some countries with endemic AI in their poultry flocks choose to vaccinate 
birds, primarily with a circulating strain of AIV.  The circulating AIV strain is 
propagated in embryonic chicken eggs and collected from the allantoic fluid, then 
chemically inactivated before being mixed with a mineral oil emulsion based adjuvant.  
This killed virus-mineral oil component vaccine is the major vaccine formulation used in 
the industry.  Although initially effective to induce some antibody production against 
homologous HA protein, studies show that current vaccine methods are only partially 
protective and also lack long-term efficacy (36, 37), further emphasizing the dire need 
for more modern and efficacious vaccine alternatives. 
 
Avian Immune System 
Avian species are phylogenetically distinct from mammals, which is clearly 
reflected in substantial differences in their immune systems.  This phylogenetic 
divergence has a practical consequence in that antibodies or standard primer sets used in 
mammalian assay systems typically perform poorly, or not at all, in avian research. 
Protein-coding open reading frames are estimated to only share 60% homology between 
avian and humans (38).  Anatomically, primary lymphoid organs in birds include the 
multi-nodular thymus, the site of T-cell maturation, and the bursa of Fabricius, the site of 
B-cell maturation, while mammals do not possess a bursa and implement B-cell 
maturation within the bone marrow (39).  Oddly enough, chickens only produce three 
classes of immunoglobulins (Ig): IgM, IgY, and IgA, while lacking the IgD and IgE 
classes (39).  Though, the IgY isotype has been found to possess a composite of IgG and 
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IgE functions, and is considered the avian equivalent to IgG (40).  Furthermore, birds do 
not possess lymphotoxins or lymphotoxin receptors needed for development of 
organized lymph nodes like mammals (41-43), and instead carry out secondary 
lymphoid functions in the spleen and regions of multiple nodular lymphoid tissues, such 
as Peyer’s patches, pyloric tonsils, or cecal tonsils (39).  On a cellular level, chickens 
possess heterophils in the place of all poly-morphonuclear cells, such as neutrophils, 
basophils, and eosinophils, which are typically present in other vertebrate animals (44-
46).  Chickens also preferentially use γδ T-cells as opposed to the αβ phenotype favored 
in mammals (47).  Upon release of the sequenced chicken genome in 2004, scientists 
were able to confirm the presence of all immune gene families in the chicken typically 
found in mammals, but chickens seem to take a more minimalist approach to immune 
gene quantity and possess reduced repertoires (43, 48).  For example, chickens have only 
retained genes absolutely necessary to maintain the use of major histocompatibility 
complex (MHC) receptors (49) and a tumor necrosis factor alpha (TNF-α) homolog is 
absent from the avian genome, despite the detection of a potential corresponding TNF-α 
receptor (48).  Chickens also lack retinoic acid inducible gene I (RIG-I) and toll-like 
receptor (TLR) 8 receptors used to detect single-stranded RNA, although the similarly 
functioning TLR7 is still present (50).  Based on this information, it is not surprising that 
birds preferentially use gene conversion mechanisms during immune repertoire 
development, despite sharing the ability to also perform traditional somatic 
hypermutation mechanisms typically used by mammals (51-53). 
Despite these differences, the fundamental steps required to mount an immune 
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response against a foreign pathogen transpire in the bird similarly to their mammalian 
counterparts (54).  Most infectious disease agents enter through mucosal tissues, either 
through the respiratory or gastrointestinal routes.  Pathogens enter these systems and 
establish, either by viral infection and replication in host cells, or bacterial use of host 
nutrients for replication.  This self-promoting process may damage the host and lead to 
disease.  During this process, the avian host’s immune system normally responds by 
attempting to clear these invading pathogens from the system.  Initially, this occurs 
through innate immunity processes that activate immediately upon detection of non-self, 
foreign entities via pattern recognition receptors (PRR) present on innate effector cells 
and B-cells.  These PRRs bind and recognize common pathogen signature motifs called 
pathogen-associated molecule patterns (PAMP), which are not biologically present in the 
avian host.  Common PAMPs include lipopolysaccharides of gram-negative bacterial 
cells walls, flagellin, or double-stranded RNA.  Detection of these unwanted pathogens 
initiates recruitment of many innate immune cells to the affected site, including 
macrophages and heterophils, both possessing phagocytic and inflammatory functions.  
If this infection is not cleared quickly, the adaptive immune response will be triggered.  
This is initiated by antigen uptake of pathogen components by professional antigen 
presenting cells (APC), a population of cells consisting of dendritic cells (DC), 
macrophages, and B-cells.  The DC will present pathogen-derived antigen to naïve T-
cells in secondary lymphoid tissues in an attempt to activate a matching lymphocyte that 
is able to recognize the specific antigen.  Should the presented antigen be recognized and 
bound by a T-lymphocyte, while receiving co-stimulatory signals, these T-lymphocytes 
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will become fully activated and undergo clonal expansion to multiply into daughter 
effector T-cells.  Effector helper T-cells will go on to provide co-stimulatory signals to 
naïve B-cells, initiating a B-cell clonal expansion and consequent antibody production 
response to the specific antigen.  In effect, all adaptive immune responses require 
professional APCs to initiate and mediate a reaction. 
 
CD40 
The CD40 co-stimulatory receptor is a member of the tumor necrosis factor 
(TNF) receptor superfamily.  This 30kDa receptor is expressed on all professional APCs 
and interaction with this receptor mediates many downstream immune functions (55).  
CD40’s ligand, CD154, also called CD40L, is expressed on helper T-cells and, upon 
CD40-CD154 ligation, recipient APCs undergo activation and enhancement of effector 
functions.  B-cells, in particular, will begin clonal expansion and robust antibody 
production (Figure 1).  This signal also aids in immunoglobulin isotype class switching 
from initial low affinity IgM to more effective isotypes (56) and drives affinity 
maturation (57).  Supplementation with soluble CD154 in vitro has been shown to 
maintain chicken B-cells under cell culture conditions (58), further emphasizing the 
importance of CD40 engagement to B-cell survival and function.  In human disease, 
patients deficient in CD40 expression suffer from hyper-IgM syndrome and lack the 
ability to produce other Ig classes and are, therefore, less able to clear pathogens which 
rely heavily on humoral immunity (59).  Some preliminary research has been completed 
with avian CD40 receptor targeting, but has primarily focused on the inclusion of 
  11 
CD154 ligand into some iteration of a vaccine to increase immunogenicity, mainly by 
expressing CD154 receptor onto bacterial vaccine vectors (60-62).   
 
 
 
Figure 1.  Abbas et al.’s diagram of basic steps to B-cell activation and 
proliferation. 
Dendritic cells must activate naïve helper T-cells, which go on to activate naïve B-cells 
through cytokine stimulation and CD40 receptor engagement to allow B-cells to undergo 
proliferation and assume effector functions. Figure modified from Abbas et al., 2007 
(54). 
 
 
CD205 
An additional receptor important to initiation of the adaptive immune response 
would be CD205.  CD205 receptor, previously known as DEC205 or Lys75, is an 
endocytic receptor capable of binding mannose through its C-type lectin domains, but 
also binds oligonucleotides such as CpG (63).  This 205kDa receptor is highly expressed 
on dendritic cells and thymic epithelial cells, and mediates antigen uptake and 
presentation.  As shown in Figure 2, CD205-expressing DCs are capable of antigen 
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presentation in either MHC-I or MHC-II context, activating CD8+ cytotoxic or CD4+ 
helper T-cells respectively (64, 65).  Higher CD205 expression on DCs is linked to 
increased antigen presentation in mice (66) and studies targeting CD205 during 
immunization were also able to increase induction of T-cell immunity (67). 
 
 
 
Figure 2.  Geijtenbeek et al.’s diagram of dendritic cell presenting antigen on 
MHC-I and MHC-II. 
CD205+ DCs are capable of presenting antigen on MHC-II to activate CD4+ helper T-
cell and cross-presentation of antigen on MHC-I to activate CD8+ cytotoxic T-cells.  
Figure modified from Geijtenbeek et al., 2009 (68). 
 
 
Avian CD205 gene structure is highly conserved when compared to its 
mammalian counterpart (69).  As expected, CD205+ DCs are highly expressed in tissues 
which mediate T-cell activation, such as chicken bursa, thymus, and spleen (69).  Very 
little research has been completed on CD205 in chickens, primarily due to the lack of 
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available reagents.  Commercial antibodies are not available for chicken CD205, nor do 
transformed chicken DCs cell lines exist for in vitro testing.  Although a method was 
described to collect bone marrow myeloid progenitor cells from the chicken to induce 
DCs differentiation with granulocyte-monocyte colony stimulating factor (GM-CSF) and 
interleukin-4 (IL-4) cytokines, this procedure is labor intensive and the culture time 
required before usable mature DCs are available can take up as much as 2-3 weeks (70).  
DCs developed from this method also differentiate ex vivo and may not be representative 
of in vivo matured, activated primary DCs.  In order to facilitate the study of chicken 
DCs and further understand the functions of the CD205 receptor, more reagents and 
methods needed to be developed for use in poultry. 
 
Antibodies in Therapeutic Use 
Antibodies have been used for therapeutic purposes since the use of antitoxins 
and antisera can counteract acute disease symptoms.  Production of such antisera is 
performed in animals, typically large mammals such as horses and donkeys, by 
immunization against the toxin or target of interest to induce development of 
neutralizing antibodies, and the antisera collected for therapeutic uses.  
Immunosuppressive drugs also utilize antibodies as a method to bind and block 
inflammatory cytokines and are commonly dispensed medications for human use.  
Antibody-based medications licensed for human use include Humira (adalimumab), 
which targets TNF-α, and HuZAF (fontolizumab), which targets interferon gamma 
(IFNγ). Both utilize monoclonal antibodies to treat chronic inflammatory diseases such 
  14 
as rheumatoid arthritis or Crohn’s disease (71).  These drugs have been highly successful 
in treating inflammatory diseases and various iterations of the anti-TNF-α monoclonal 
drugs have been manufactured (golimumab marketed at Simponi, infliximab marketed as 
Remicade, and certolizumab pegol marketed as Cimzia) (71, 72).  This type of passive 
immunization primarily uses antibodies for their blocking and neutralizing functions.  In 
contrast, some therapeutics utilize the ability of antibodies to imitate naturally occurring 
receptor-ligand interactions to induce specific downstream functions (73).  The use of 
these so-called agonistic antibodies is not as well established as the use of neutralizing 
antagonistic antibodies, but this research field and its potential applications are vast.   
Agonistic antibodies function by mimicking the action of a naturally binding 
ligand to a specific receptor to induce controlled activation and downstream functions 
specific to that receptor (74).  This is typically achieved by creation and screening of 
antibody candidates during monoclonal antibody development to ensure the selected 
antibody both binds and activates - as opposed to merely bind.  The majority of antibody 
therapy studies have been completed in murine and human systems (75), primarily as a 
method to treat and clear cancerous cells (76).  The most extensively studied immune 
receptor studied for this type of therapy is the CD40 receptor (77, 78).  Although 
activation of this receptor on APCs typically induces a pro-inflammatory immune 
response, this receptor is also highly expressed on cancerous cells which undergo 
apoptosis when engaged by agonistic anti-CD40 antibodies (79).  Immunization with 
agonistic anti-CD40 antibodies combined with soluble cancer antigen target has recently 
been shown to stimulate development of cancer-specific T-cells reaching up to 60% of 
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the total T-cell population in mice (80).  Antibody targeting and Fc receptor 
manipulation has been quite successful in this regard, with studies showing effective 
induction of antibody-dependent cell-mediated cytotoxicity or complement dependent 
cytotoxicity (81).  A recent study has shown targeting with an IgE antibody against a 
specific cancer marker to be even more effective at clearing cancerous cells than IgG by 
harnessing the system originally designed for parasite clearance and therefore increasing 
macrophage phagocytic activity (82).  This may be another avenue to pursue in disease 
research, particularly in designing methods to induce specific immune response 
pathways using agonistic antibody-mediated targeting. 
 
Antibody-Guided Complexes 
An initial mouse study by Barr et al. in 2003 illustrated that conjugation of 
antigen to anti-CD40 monoclonal antibodies was able to increase antibody responses 
against the specified antigen using less reagent (10µg) compared to immunization of a 
mixed solution of unconjugated anti-CD40 and antigen.   Previous administration of 
anti-CD40 monoclonal antibodies mixed with antigen required delivery of higher 
dosages ranging from 100µg to 250µg of antibodies to increase immunogenicity against 
the antigen (83-85).  Administration of anti-CD40 antibody without antigen conjugation 
has also been associated with several negative side effects, such as general polyclonal 
activation of B-cells and increased incidence of splenomegaly in mice (86).  The 
transition to direct conjugation of antigen to CD40-targeting antibodies was able to 
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mitigate these negative side effects in mice while maintaining immunogenicity using a 
reduced amount of targeting antibody and antigen. 
In response to this research, the Berghman laboratory developed an agonistic 
monoclonal antibody against chicken CD40 protein receptor, designated as 2C5, capable 
of stimulating proliferation of serum-starved B-cells and also activating chicken 
macrophages in vitro based on nitric oxide assays (87).  These agonistic antibodies were 
used to present antigen directly to professional APCs in an effort to induce rapid 
immune responses (88).  This was accomplished by biotinylation of the anti-CD40 
antibodies and the synthetic peptide immunogen, and then using streptavidin as a 
scaffold to create a complex containing two anti-CD40 antibodies and two peptide 
immunogens held together by one streptavidin (Figure 3).  This antibody-guided 
complex was administered subcutaneously into birds and serum collected to monitor 
subsequent immune response.  Peptide-specific IgY antibodies, the avian equivalent of 
mammalian IgG, were detected in serum as early as 4 days post-immunization, 
continued to increase at 7 days, peaked at 10 days, and began to wane at 14 days post-
immunization.  This experiment demonstrated that the guided-antibody complex was 
capable of inducing robust antibody production, as well as rapid antibody isotype 
switching from less desirable IgM to IgY antibodies in chickens.  When administered via 
different routes such as oral, eye drop, cloacal, or subcutaneous, this complex was able 
to induce statistically significant increased peptide-specific circulatory IgY levels, as 
well as measurable secretory IgA levels from tracheal wash samples when compared to 
the non-guided complex control groups (89). 
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Figure 3.  Schematic of antibody-guided complex loaded with peptide antigen. 
Anti-CD40 monoclonal antibodies (Ab) were biotinylated and attached to a streptavidin 
scaffold at a ratio of 2 anti-CD40 : 1 streptavidin : 2 peptide antigen.  The resulting 
complex was used for immunization in chickens to provide both target antigen and co-
stimulatory binding signals to antigen-presenting cells. 
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The CD40-targeting antibody-guided complex was shown to effectively induce 
antibody production in chickens, but the following questions remain to be fully 
investigated.  Are there other potential uses for this system beyond a vaccine delivery 
platform?  Can immunogens beyond short synthetic peptides be loaded onto the system 
without negatively impacting efficacy?  And how efficacious is this platform as a 
vaccine?  Furthermore, the potential of targeting other immune receptors for antibody-
guided immunization in chickens has also not been fully examined.  Ligation of different 
immune receptors would render different responses; depending on the desired response, 
this may be preferable as an alternative to solely targeting CD40. 
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CHAPTER II  
A FAST AND INEXPENSIVE PROTOCOL FOR EMPIRICAL VERIFICATION OF 
NEUTRALIZING EPITOPES IN MICROBIAL TOXINS AND ENZYMES* 
 
Introduction  
 Inducing antigen-presenting cell activation and effector responses requires both 
binding of a specific antigen by the APC and co-stimulatory signals received from helper 
T-cells.  Binding and activation of the CD40 receptor on B-cells emulates the germinal 
center environment and triggers downstream rapid antibody production and isotype 
switching against a specific antigen (55).  Manipulation of this system would be 
beneficial for controlled guidance of the immune system’s reactivity against a defined 
target, specifically by using agonistic monoclonal antibodies against the CD40 receptor 
loaded with an antigen of interest.  These CD40-targeting antibody-guided complexes 
have previously been tested for use as in vivo delivery systems for vaccines (91-93).  In 
poultry, this CD40-targeting approach has been shown to induce robust and specific IgG 
serum antibody responses within one week (88), as well as secretory IgA production in 
the mucosal samples (89), essentially bypassing the weaker - chiefly IgM - initial 
immune response associated with primary immunizations.  The application of this 
guided complex to induce rapid antibody production beyond its initial vaccine 
                                                
*Reprinted with permission from “A fast and inexpensive protocol for empirical 
verification of neutralizing epitopes in microbial toxins and enzymes” by Vuong CN, 
Chou WK. Kuttappan VA, Hargis BM, Bielke LR, and Berghman LR, 2017.  Front. in 
Vet. Sci., 4:91.  Copyright 2017 by Christine N. Vuong (90). 
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designation has not been exploited.  To assess the capabilities of the antibody-guided 
immunization system, Clostridium perfringens alpha toxin (Cpa) was used as a model 
microbial toxin for rapid antiserum production and downstream epitope mapping. 
 Alpha-toxin is one of many toxins produced by Clostridial bacteria and possesses 
both hemolytic and phospholipase C (PLC) enzymatic activities, making it an ideal 
model for epitope mapping.  Neutralizing antibodies can be produced against specific 
regions of the toxin to test the antibody’s ability to inhibit one or both of the toxin’s 
enzymatic functions.  In poultry, C. perfringens is the causative agent responsible for 
necrotic enteritis and continues to be an obstacle for the industry (94, 95).  Although part 
of the commensal gut flora, C. perfringens can cause disease when an altered gut 
microenvironment or pre-established intestinal damage facilitates abnormal overgrowth 
and microbial dysbiosis in the gut (11).  This imbalance results in intestinal lesions 
caused by the bacterium’s multiple toxins and leaky gut syndrome in the bird (96, 97).  
Although alpha-toxin is no longer considered the sole toxin to target for vaccine 
development (23), a rapid method to determine the regions required to neutralize a 
toxin’s activities would be of significant interest.  Previous epitope mapping studies have 
primarily utilized site-directed mutagenesis, but this method requires specific base 
changes, molecular cloning, and downstream expression and purification before the 
altered toxin can be tested for change in function (22, 26-28).  Introduction of a less 
expensive and more rapid epitope mapping method would be beneficial for researchers 
attempting to identify essential regions on a protein or candidate targets for therapeutics.   
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 In this study, C. perfringens alpha-toxin was used as a model microbial toxin for 
epitope mapping to determine whether the antibody-guided immunization method has 
potential to be used for rapid identification of targets for downstream toxin 
neutralization or vaccine development.  A panel of linear peptide epitopes spanning the 
majority of the Cpa’s amino acid sequence was synthesized.  The synthetic peptides 
were incorporated into the antibody-guided immunogen complex and administered in 
chickens for polyclonal IgG production.  The peptide-specific antisera produced were 
used for downstream in vitro neutralization testing against the toxin’s hemolytic and 
phospholipase C enzymatic functions, respectively.  Using Cpa as a model toxin, this 
approach expands the function of antibody-guided immunization complexes beyond its 
initial use as a delivery system in poultry and highlights its potential as a method for 
rapid IgG production/reagent development, and as the fastest method to deliver proof of 
concept of potential toxin and enzyme neutralization strategies. 
 
Materials and Methods 
Peptide epitope design 
 Hydrophilic segments ranging from 9-23 amino acids in length were designed 
based from the 398 amino acid Clostridium perfringens alpha toxin sequence (GenBank 
Accession CAA35186.1) using Immune Epitope Database and Analysis Resource 
(IEBD) open-source predictive algorithms to construct a peptide library (98).  The 
library consisted of 23 peptide epitopes in order to provide maximum coverage of the 
primary structure of the toxin while maintaining ease of synthesis (Table 1); peptides 
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were designated as numbers 1-23 based on starting position on the original Cpa toxin 
sequence (Figure 4).  Hydrophobic stretches of the Cpa toxin were omitted to avoid 
peptide synthesis issues.  Only consecutive linear regions of the alpha toxin were 
selected for synthesis to avoid the time and expense associated with the protein 
expression and purification required to produce conformational epitopes.  Biotinylated 
commercially-synthesized peptides (Genscript, Piscataway, NJ) were incorporated 
stochiometrically in the antibody-guided immunization complex as described previously 
(88). 
 
 
 
Figure 4.  Schematic of 23 peptides generated based on C. perfringens alpha toxin 
amino acid sequence. 
Linear peptides were selected based on ease of synthesis using IEDB publically 
available B-cell epitope prediction algorithms (98). (Figure not to scale.) 
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Table 1.  C. perfringens alpha toxin-derived synthetic peptides.   
Design based on Cpa GenBank Accession: CAA35186.1 amino acid sequence. 
Peptide # Start Position Length Sequence 
1 31 9 GKIDGTGTH 
2 51 15 ENDLSKNEPESVRKN 
3 71 20 ENMHELQLGSTYPDYDKNAY 
4 81 20 TYPDYDKNAYDLYQDHFWDP 
5 91 20 DLYQDHFWDPDTDNNFSKDN 
6 117 10 IPDTGESQIR 
7 136 10 EWQRGNYKQA 
8 158 23 DIDTPYHPANVTAVDSAGHVKFE 
9 170 20 VDSAGHVKFETFAEERKEQY 
10 181 20 TFAEERKEQYKINTAGCKTN 
11 191 21 KINTVGCKTNEDFYADILKNK 
12 200 20 EDFYADILKNKDFNAWSKEY 
13 210 20 KDFNAWSKEYARGFAKTGKS 
14 220 17 ARGFAKTGKSIYYSHAS 
15 233 17 SHASMSHSWDDWDYAAK 
16 240 20 SWDDWDYAAKVTLANSQKGT 
17 270 16 DVSEGNDPSVGNNVKE 
18 291 12 STSGEKDAGTDD 
19 309 13 KTKDGKTQEWEMD 
20 320 21 DNPGNDFMAGSKDTYTFKLKD 
21 330 20 SKDTYTFKLKDENLKIDDIQ 
22 354 16 RKRKYTAFPDAYKPEN 
23 379 19 VVDKDINEWISGNSTYNIK 
 
 
Antibody-guided immunogen complex 
 Immunization complexes were produced as previously described by Chen et al. 
(2012).  Biotinylated CD40-targeting antibodies were complexed with each synthetic 
peptide using streptavidin as a scaffold.  Antibody-guided complexes were 
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stoichiometrically produced to contain a molar ratio of 2 antibodies and 2 peptides to 
every 1 streptavidin.  Non-targeting complexes were also produced by replacing CD40-
targeting antibody with normal (non-targeting) mouse IgG and served as negative 
controls.  Non-targeting control complexes incorporated either peptide #13 or #14 and 
were further designated as 13C and 14C, respectively. 
 
Immunizations 
 Seventy-five six-week-old broilers were divided into sets of three, creating a total 
of 25 groups.  Animal care and handling was approved by Texas A&M University 
Institutional Animal Care and Use Committee (permit #2013-0254).  Because chickens 
are outbred animals and were expected to exhibit divergent immune response levels, 
each peptide candidate was administered to three birds to ensure at least one good 
responder.  Pre-immune serum was collected from all birds and designated as Day1 
samples.  Each group of birds was subcutaneously immunized with 50ug of antibody-
guided complex carrying one of the twenty-three peptides.  Two extra groups of birds 
were immunized with non-targeting antibody complex (as negative controls), using 
either peptide #13 or #14, and are further referenced as control groups 13C or 14C.  
Serum was collected one week-post immunization and designated as Day7 samples; 
these samples were used for in vitro antibody titer measurements and toxin 
neutralization assays.   
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ELISA 
 Goat anti-biotin IgG and the biotinylated target peptides with pre-mixed at a 1:1 
molar ratio.  This pre-mix was coated onto 96-well microtiter plates at a concentration of 
5ug/mL in carbonate-bicarbonate coating buffer, pH 9.6.  Wells were blocked with 5% 
(w/v) bovine serum albumin (BSA) in phosphate buffered saline (PBS) and serum 
samples were applied at 1:50 dilution.  Samples were incubated for 2 hours at 37°C 
before peroxidase-conjugated goat anti-chicken IgG detection antibody was applied 
(Jackson ImmunoResearch, West Grove, PA).  Peroxide/tetramethylbenzidine (TMB) 
substrate system was used as the colorimetric endpoint and enzymatic reactions halted 
with 2M sulfuric acid.  Absorbances were read at 450nm using a Perkin-Elmer Victor 2 
plate reader (Waltham, MA).  Antibody titers were reported as Day7:Day1 ratio to 
correct for interference from pre-existing cross-reactive antibodies in circulation.  No 
statistical analysis was performed as only qualitative responses, production of any 
neutralizing antibodies for use in downstream assays, were needed for study.   
 
Hemolytic neutralization and phospholipase C neutralization assays 
 Purified C. perfringens alpha toxin was obtained from the United States 
Department of Agriculture (USDA) Animal and Plant Health Inspection Service 
(APHIS) and used at a working dilution of toxin in sterile PBS for neutralization assays, 
as recommended by the manufacturer.  Antisera from the two highest responders of each 
group, based on previously performed enzyme-linked immunosorbent assay (99), were 
used for hemolytic neutralization testing.  Sera were titrated by 2-fold serial dilution 
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starting from an initial 1:10 starting dilution on a microtiter plate in a 50µL volume, and 
then mixed 1:1 v/v with the working stock of alpha-toxin.  Toxin and sera were 
incubated at 37°C for 1 hour to allow potential binding/neutralization of the toxin.  After 
initial incubation, 100µL of 5% (v/v) sheep red blood cells diluted in PBS were added 
and incubated for another hour at 37°C.  After incubation, neutralization of hemolytic 
activity was observed.  Phospholipase C neutralization assays were performed using the 
same procedure, but modified for the application of 10% (v/v) egg yolk emulsion as a 
source of phospholipids, in lieu of red blood cells.  Neutralization titers are reported as 
the inverse of highest serum dilution factor capable of fully neutralizing the enzyme.  
Because each peptide candidate was only represented by two antisera samples and 
reported in inverse dilution factor, standard errors are not included.  Statistics to compare 
between groups was not performed, as only qualitative data showing ability to neutralize 
were needed to determine whether a specific region is a suitable target or not; antibodies 
against any region able to neutralize both enzymatic activities would have been 
considered an indicator for potential candidate after epitope mapping. 
 
Results 
Peptide-specific polyclonal IgY rapidly produced using antibody-guided immunization 
 All groups of birds mounted humoral immune responses against their respective 
peptide immunogen within 7 days of immunization (Figure 5), as measured by peptide-
specific IgG titers via ELISA.  As expected, control groups receiving peptide loaded 
onto non-targeting complexes also mounted low level antibody responses against the 
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peptide, but these responses did not reach the overall robust levels induced by CD40-
targeted peptide delivery.  Individual immune responses varied, as anticipated from 
outbred birds.  Statistical analysis to compare response between groups was not 
necessary as only qualitative responses, production of any neutralizing antibodies for use 
in downstream assays, were needed for this study. 
 
 
 
Figure 5.  Peptide-specific IgG responses.   
Individual peptide-specific antibody titers reported as Day7:Day1 ratio based on ELISA 
measurements against the matching peptide used for immunization.  Groups 13C and 
14C were immunized with non-targeting complexes loaded with either peptide #13 or 
#14 and served as non-targeting negative controls. Group means and standard error 
overlaid. 
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Blocking/binding Cpa linear epitopes sufficient for neutralizing hemolytic activity, but 
not PLC activity 
 As seen in Figure 6, all tested antiserum samples were able to neutralize in vitro 
Cpa hemolytic activity to varying degrees (individual titers ranging from 80 to 320), 
suggesting antibody binding of any accessible region on the toxin itself is sufficient to 
block hemolytic activity.  Of note, groups 13C and 14C also produced some peptide-
specific antibodies, as measured by ELISA, but these antibodies were unable to 
neutralize hemolytic activity.  This suggests antibodies produced against epitopes loaded 
onto antibody-guided complexes have gone through some affinity maturation and bind 
more efficiently than the immunization using the non-targeting counterparts.  In contrast 
to the hemolytic neutralization results, none of the serum samples from the experimental 
groups were able to neutralize Cpa’s phospholipase C activity (Figure 7).  
Hyperimmunized chicken antisera against native C. perfringens obtained from USDA-
APHIS were used as a positive control in neutralization assays and were capable of 
neutralizing PLC activity.  The hyperimmune antisera would possess an assortment of 
antibodies against various regions and spatial conformations of Cpa, implying that the 
critical site responsible for PLC activity cannot be emulated by a synthetic linear 
peptide.   
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Figure 6.  Mean hemolytic neutralization titers.    
Mean hemolytic neutralization titers.  Hemolytic neutralization titers reported as the 
inverse of the highest serum dilution factor capable of completely neutralizing Cpa 
toxin’s hemolytic activity.  Hyperimmune serum against alpha toxin obtained from 
USDA APHIS was used as positive control serum and the corresponding group was 
labeled as “+” on chart. 
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Figure 7.  Mean phospholipase C neutralization titers.   
PLC neutralization titers reported as the inverse of the highest serum dilution factor 
capable of completely neutralizing Cpa toxin’s PLC activity.  Hyperimmune serum 
against alpha toxin obtained from USDA APHIS was used as positive control serum and 
the corresponding group was labeled as “+” on chart. 
 
 
Discussion 
 Antibody-guided complexes were initially designed for use as a vaccine delivery 
system, but this technique clearly has potential to also become an analytical tool to 
rapidly dissect molecules into their various active domains and pinpoint essential motifs 
underlying specific biological activities.  This system has the added advantages of being 
both quicker and more cost-effective than standard site-directed mutagenesis procedures.  
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The antibody-guided method used in this experiment was purposely limited to presenting 
linear epitopes; it appeared that those did not produce antibodies capable of neutralizing 
PLC activity.  Although unable to identify a PLC-neutralizing region on the Cpa, this 
procedure has proven useful for rapid polyclonal antiserum production/reagent 
development for research purposes.  Because a multitude of antigen targets, linear or 
conformational, can be designed and readily incorporated into this system, the use of 
antibody-guided complexes beyond its original platform can be appreciated.   
 Interestingly, the results suggest that binding to any continuous epitope of the Cpa 
is sufficient to block its hemolytic activity, but not to neutralize its PLC activity.  As 
only linear peptides were tested, this suggests neutralization requires binding and 
blocking of one or more conformation-dependent regions on the toxin itself to inhibit 
PLC functions (100).  Removal of the toxins’ enzymatic activities requires modification 
of the sequence during recombinant design or chemical inactivation of purified toxins in 
order to render them safe for previous vaccine efforts.  These modifications may alter the 
conformation of the toxin itself, and therefore efforts to make the tested vaccines safer 
have actually caused them to be less efficacious (18, 101).  Results from this study 
support previously reported data in which altered toxin used as a vaccine target was 
unable to induce production of neutralizing antibodies or fully protective immune 
responses.  Due to these findings, targeting a single toxin may not be the answer for 
controlling NE.  Preventing overgrowth of C. perfringens by preemptive nutritional and 
biosecurity control procedures to maintain gut health or developing therapeutics capable 
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to blocking overgrowth of the bacterium itself may, at least for the time being, be more 
effective solutions. 
 This antibody-guided immunization technique is designed to target chicken CD40, 
a unique concept for antiserum production instead of the commonly used mouse, rabbit, 
or goat hosts.  The phylogenic divergence between avian and mammalian systems allows 
this method to be potentially used for antiserum production against commonly conserved 
mammalian target epitopes that have previously proven non-immunogenic in 
mammalian hosts.  Avian host systems also permit the collection of eggs, which contain 
the specific antibody of interest within the yolk, decreasing blood collection 
requirements and associated stress on the animal.  Avian IgG antibodies produced by 
antibody-guided immunization are suitable for laboratory research use, development of 
diagnostic assays, as well as epitope mapping using linear epitopes.  Biotinylated 
peptides can be easily and inexpensively synthesized in as little as a week, incorporated 
into the antibody-guided complex, and birds can be immunized for an initial serum 
collection as early as one-week post immunization.  Conformational epitopes can also be 
targeted with this system, but would require more time and expense to generate before 
proceeding to in vivo immunizations.  Although antiserum production with this method 
is a viable option with conformational epitopes, it does not lend itself well for epitope 
mapping.  This specific study has provided proof of principle for the use of antibody-
guided immunogen complexes to quickly produce antibodies for epitope mapping 
verification. 
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CHAPTER III   
DELIVERING INACTIVATED AVIAN INFLUENZA TO ANTIGEN PRESENTING 
CELLS BY TARGETING CD40 FOR ENHANCED PROTECTION AGAINST 
LETHAL CHALLENGE 
 
Introduction  
The CD40 receptor expressed on all professional APCs is responsible for 
mediating the release of co-stimulatory and pro-inflammatory cytokines enhancing 
immune response activity during infection.  This includes activation and proliferation of 
macrophages, B-cell affinity maturation and isotype switching from low intrinsic affinity 
IgM to more effective IgG and IgA isotypes, and releasing chemokines to recruit other 
immune cells to effector sites (56, 57).  This response typically requires 2-3 weeks to 
develop because the target antigen must make contact with the APC while the cell is also 
provided with helper T-cell co-stimulatory signals to induce downstream activation 
responses (55).  Given the significance of its abilities, intentionally targeting CD40 to 
enhance immune responses during immunization is a reasonable approach.  Agonistic 
anti-CD40 antibodies can act as surrogate co-stimulatory signal from the helper T-cell 
while physically loading antigens to the anti-CD40 antibody would allow direct delivery 
of the target immunogen to the APC, circumventing the time typically needed to initiate 
this response (86).  Antibody-guided immunization methods have grown in popularity 
owing to their ability to directly present antigen to APCs, inducing more robust immune 
responses in a shortened time period (74, 102).  CD40 receptor targeting in particular has 
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been the most extensively studied immune receptor targeting mechanism, primarily in 
human and murine systems (77, 78, 103).  Agonistic CD40 antibody is likely to be used 
in live animal treatments given the availability to use the same antibody for different 
mammalian species (104).  Previous research using CD40-targeted complexes for 
immunization in poultry has shown a surge in immunogenicity by inducing both 
systemic IgG and mucosal IgA responses after a single administration (88, 89).  This is 
particularly important for respiratory diseases, as secretory IgA is the main element 
protecting birds during mucosal infection (105, 106) and the CD40 activation pathway is 
the singular mechanism capable of inducing immunoglobulin isotype-switching in birds 
(107).  
Although AIV is not endemic to poultry within the United States, AIV remains a 
large issue for other countries and a near-constant biosecurity issue within the US, as 
emphasized by the recent 2014-2015 highly pathogenic avian influenza (HPAI) outbreak 
which caused an estimated loss of approximately 48 million birds and the 2016 Indiana 
outbreak which resulted in a loss of over 400,000 birds (33).  Current AIV vaccines 
center their protection on development of protective antibodies against the virus’ HA 
protein (35, 108, 109).  This is problematic as there are 16 different subtypes of HA, 
requiring vaccine propagation and reformulation as different outbreaks occur (110).  The 
M2 ion channel’s extracellular (M2e) region of AIV has been identified as a conserved 
epitope among most Type A influenza strains and many attempts have been made to use 
this domain for development of a universal vaccine, but with variable results (111-113).  
An effective protective response correlates with sufficient antibody titer against the HA 
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protein, which relates with virus neutralization.  Some vaccines against highly 
pathogenic AIV have proven to be only partially protective due to mismatched antigen 
compared to the field virus, and a lack long-term efficacy, leading to the need to 
investigate potential vaccine efficacy enhancers (36, 37, 114, 115). 
The antibody-guided adjuvant complex delivery system has been previously 
tested for use in poultry, but has so far been limited to presentation of synthetic peptides 
and observation of immunogenicity (88, 89).  Using this established chicken CD40-
targeting/antibody-guided adjuvant complex in combination with anti-M2e monoclonal 
antibodies (Figure 8), this modified complex could potentially bind inactivated avian 
influenza virions (iAIV), regardless of HA type.  Avian influenza virus was selected as 
the pathogen target due to its monofactorial disease causation and well-defined 
benchmark for functional protection (survival past 4 days post-challenge), making it an 
ideal candidate target for testing proof of concept.  This approach in theory has the 
potential to overcome the weak response and short-term protection issues of some AIV 
vaccines (92).  The novel use of anti-M2e antibodies in the complex in order to 
universally bind whole avian influenza viruses to the targeting-complex will permit the 
use of this enhanced delivery system regardless of the subtype of the circulating virus.  
In this study, the antibody-guided adjuvant system, specifically targeting the chicken 
CD40 receptor of antigen presenting cells, was tested for the ability to present 
inactivated HPAI virus and confer functional protection upon homologous challenge in 
chickens. 
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Figure 8.  Antibody-guided adjuvant complex schematic.   
Anti-cCD40 monoclonal antibodies (Ab) and anti-AIV M2e monoclonal antibodies were 
directionally biotinylated on their carbohydrate moieties and attached to a streptavidin 
scaffold at a ratio of 2 anti-CD40 : 1 streptavidin : 2 anti-M2e.  The resulting complex 
was mixed with 384 HAUs of inactivated AI virus, which incorporates the virus into the 
vaccine complex.  This complex was used for immunization in chickens. 
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Materials and Methods 
Viruses 
Inactivated A/Turkey/Virginia/158512/2002 H7N2 low pathogenic avian 
influenza (LPAI) virus was used to coat ELISA plates during anti-M2e monoclonal 
antibody screening.  A/Egret/Hong Kong/757.2/2002 H5N1 HPAI was used for initial in 
vivo testing of three different anti-M2e monoclonal antibody candidates on modified 
antibody-guided complex.  Immunogenicity trials used inactivated 
A/Turkey/Wisconsin/1968/H5N9 LPAI virus.  The challenge trial also used Egret/02 
H5N1 HPAI virus.  All viruses were propagated in chicken embryo allantoic fluid.  
Viruses utilized for vaccination or hemagglutination inhibition (HI) assays were beta-
propiolactone inactivated (116).  Vaccines were formulated to contain 384 
hemagglutination units (HAU) of virus per dose.  HI assays were performed with the 
identical virus used during corresponding immunization. 
 
Anti-M2e monoclonals 
 Monoclonal antibodies were produced against the extracellular domain of avian 
influenza virus’ M2 ion channel protein.  Hybridomas were created with Sp2/0 mouse 
myeloma cells using standard electrofusion protocols (87).  Splenocytes were harvested 
from mice hyper-immunized against synthetically produced peptide conjugated to 
keyhole limpet hemocyanin (KLH) (GenScript, Piscataway, NJ) containing the M2e 
amino acid protein sequence (EVETPTRN).  The M2e peptide sequence selected had 
100% consensus with over 50 different strains of avian influenza in the GenBank protein 
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sequence database.  Mouse work procedures were carried out in accordance with permit 
2014-0013, as approved by the Texas A&M University Institute of Animal Care and Use 
Committee.  Hybridomas were screened and selected based on production of IgG 
antibodies specific against the synthetic M2e peptide via enzyme-linked immunosorbent 
assay (99) as well as against whole inactivated Turkey/02 H7N2 LPAI virus (117).  
From the original 15 double positive (against peptide as well as whole virus) parent 
hybridomas, three parents were selected for further subcloning.  Subclones were 
screened again against the peptide and whole AIV.  From the pool of hybridoma 
subclones which remained double positive, one subclone from each parent was selected 
(creating a panel of three potential candidates which were designed clones A, B, and C) 
for further screening and use in downstream adjuvant complex formation and trials. 
 
Anti-M2e monoclonal selection 
 Upon cloning by limiting dilution, three monoclonals were selected as potential 
candidates for immunization complex formulation, designated as clones A, B, and C.  
The respective monoclonal antibodies were incorporated into the CD40-targeting 
complex as previously described (88), with minor modifications in that biotinylated anti-
M2e monoclonal antibodies were substituted for previously described biotinylated 
peptide antigens.  This created a complex comprising four biotinylated monoclonal 
antibodies (two against the chicken CD40 receptor and two against AIV M2e, see Figure 
8) on a central streptavidin scaffold molecule.  This antibody-guided complex was then 
mixed with a fixed amount of iAIV.  The initial virion to complex incorporation ratios 
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tested included 250, 500, 1000, 2000, 4000, 8000, and 16000 virion units per complex  
(n=20 birds per dosage per candidate monoclonal).  Each vaccine dose consistently 
contained 384 HAU of inactivated Egret/02 H5N1 HPAI virus, propagated in allantoic 
fluid.  The resulting adjuvant complex was mixed 1:1 v/v with sterile saline containing 
5% (v/v) squalene and 0.4% (v/v) Tween 80 for subcutaneous administration. Virion-
loaded complex was administered to two-week-old layers obtained from Medion 
Vaccine Company (Bandung, Indonesia).  Serum was collected one week post-
immunization to measure serum hemagglutination inhibition (HI) titers against 
homologous iAIV.  HI titer data were converted to Log2.  For immunogenicity 
comparisons, each clone’s dosage (viral particle : complex ratio) data were combined 
and averaged prior to comparison with the other clones, making results reported for each 
monoclonal candidate from an n=140.  ANOVA and post-hoc Tukey HSD analysis were 
performed using JMP statistical software, version 12.  P-values ≤ 0.05 were considered 
statistically different.  This study was carried out in accordance with the Indonesian 
government’s biosafety level 3 animal use regulations.   
 
Vaccine preparation 
 Further adjuvant complex studies were performed using clone C anti-AIV M2e 
monoclonal antibodies.  This vaccine was mixed with iAIV at a 1000X virion to 
complex ratio, with each vaccine dose containing 384 HAU of iAIV as previously tested.  
Guided complex was administered via either subcutaneous, oral, or eye drop (oculo-
nasal) routes, depending on the trial.  Subcutaneously administered guided complex was 
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prepared as previously stated, while the orally-administered complex was alginate-
encapsulated in sterile saline before administration as described in detail in (89).  Eye 
drop administered complex was used directly without any additional preparation.  A 
control group receiving mineral oil emulsion based vaccine containing 384 HAU of 
iAIV used as a reference control during initial screening for anti-M2e monoclonal 
screening and during the final challenge trial. 
 
Immunogenicity optimization 
 Male Leghorn chickens (n=10/group) were either subcutaneously, orally, or via eye 
drop vaccinated at two weeks of age.  Beta-propiolactone-inactivated Turkey/68 H5N9 
LPAI virus was used for immunization as well as downstream HI assays.  Pre-immune 
sera were collected at the start of the study and post-immunization sera were collected 
for up to 4 weeks.  Serum samples were used in HI assays against the same iAIV used 
during immunization.  The HI assays were performed as follows: a 2-fold serial dilution 
of the serum samples was mixed 1:1 v/v with 8 HAU of the inactivated AIV used in 
formulation of the vaccine complex followed by the addition of 5% red blood cells.  
Reciprocal of the highest serum dilution capable of hemagglutination inhibition was 
considered the final HI titer; these HI titers were converted to Log2 values and used for 
statistical analysis.  Analysis of variance (ANOVA) and post-hoc Tukey HSD analysis 
performed using JMP statistical software, version 12.  P-values ≤ 0.05 were considered 
statistically different.  Bird procedures followed standard practices set by the University 
of Arkansas Institutional Animal Care and Use Committee. 
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Challenge trial 
Specific pathogen-free Leghorn chickens were obtained from Medion Vaccine 
Company for use in this study and animal care and procedures conducted in accordance 
with Indonesian government biosafety level 3 animal regulations.  Inactivated Egret/03 
H5N1 HPAI virus was used for guided complex preparation and the live virus was used 
during challenge.  Birds were immunized with antibody-guided complex loaded with 
inactivated H5N1 HPAI virus, final volume 0.5ml, at two weeks of age, either 
subcutaneously at the nape of the neck or orally (n=25 birds per group).  Groups were 
boosted at four weeks of age.  One group received commercial oil emulsion based 
vaccine at 10 days of age (no boost) and was used as a point of reference for the 
experimental groups.  All groups were challenged with 200µL of 1x106 50% embryo 
infectious dose (EID50)/mL homologous HPAI through the intranasal route at five-
weeks-of-age.  Percentage of group survival 4days post-challenge was calculated and 
used as an indicator for protective efficacy, as the standard mortality rate of HPAI 
challenge in birds is 75-100% within 4 days (118). 
 
Results 
Antibody-guided inactivated virion is able to induce neutralizing IgG antibody titers 
against AI 
 Each candidate anti-M2e monoclonal antibody was used to form an antibody-
guided complex (two anti-M2e antibodies along with two anti-cCD40 antibodies onto a 
central streptavidin scaffold molecule).  Each candidate adjuvant complex was mixed 
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with 384 HAU of inactivated virus and administered to birds for immunogenicity 
comparison.  This test would also confirm that the addition of the anti-M2e antibody-AI 
virus to the original complex does not sterically hinder the binding and activation of the 
CD40 receptor.  Based on anti-AI titers measured by HI titer one week post-
immunization, clone C induced statistically greater responses than clones A and B, as 
well as the traditional mineral oil emulsion vaccine formulation (Figure 9).  Based on 
this evidence, all further testing was conducted using clone C anti-AIV monoclonal 
antibody.  No clear immunogenicity differences were observed between compositions 
with different virion:complex ratio), thus a 1,000X ratio was used for subsequent studies.  
(Individual dosage ratio response data are not shown, but averaged titers for all dosages 
are presented as mean response per candidate clone in Figure 9.) 
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Figure 9.  Clone C was the most immunogenic of the three candidate anti-M2e 
monoclonal antibodies.   
Each candidate monoclonal antibody (clones A, B, or C) was combined with 384 HAU 
inactivated Egret/02 H5N1 HPAI AIV.  Different ratios of antibody complex mixed with 
fixed 384 HAU of iAIV were tested, with dosages ranging from 250 to 16000 times 
virus particle to guided-complex ratios.  AIV-loaded complex was used for 
immunization of chickens and sera were collected one week post-immunization for HI 
assays.  A group receiving oil emulsion based vaccine was used as a reference.  As no 
dose-dependent effects were observed in the viral particle:complex dosage ratios tested 
(250-16000), HI titers of each candidate (clones A, B, or C) are presented as the mean of 
all ratio ranges for each clone.  Significantly different HI titers are indicated with non-
matching letters.  Clone C induced significantly higher HI titer compared to all other 
groups. 
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Subcutaneous prime required for induction of AIV neutralizing antibodies 
 Optimization of adjuvant complex administration used inactivated Turkey/68 
H5N9 LPAI with a combination of subcutaneous, oral, or eye drop routes in a two-week 
interval prime/boost schedule.  Based on serum HI titer data collected 1, 2, and 4 weeks 
post-boost (Figure 10), subcutaneous prime is required to induce immunogenicity and 
produced statistically higher HI titers compared to non-subcutaneous counterparts.  
Groups receiving only oral/eye drop administration of the vaccine complex did not 
produce neutralizing antibodies against the virus and were essentially non-responsive.  
The group receiving both subcutaneous prime and boost mounted the greatest immune 
response, with HI titers statistically higher than all other groups.  Interestingly, the group 
receiving a subcutaneous prime only (no boost received) retained measurable levels of 
neutralizing antibodies up until the latest time point, i.e. 6-weeks post immunization for 
this group. 
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Figure 10.  Subcutaneous administration induces the highest immune response. 
Immunogenicity trials tested subcutaneous (S.C.), oral, or eye drop administration of the 
vaccine complex (prime at 2 weeks of age and boost at 4 weeks of age).  Serum HI titers 
were measured at 1, 2, and 4 weeks (W) post-boost.  Significantly different HI titers 
between groups at each time point are indicated with non-matching letters.  Results show 
that subcutaneous administration is required to induce a robust response.  Birds primed 
and boosted subcutaneously had significantly higher HI titers than birds receiving only 
one subcutaneous injection.  No response was observed in birds receiving non-
subcutaneous administrations.   
 
 
Subcutaneously administered guided complex is able to protect birds against HPAI 
challenge 
 Antibody-guided complex was able to confer protective immunity following lethal 
H5N1 HPAI challenge when birds were immunized subcutaneously (Table 2).  
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Protection was measured as survival 4 days post-challenge with the homologous 
Egret/03 H5N1 HPAI.  The group immunized subcutaneously with both prime and boost 
yielded a 100% survival rate after challenge, matching survival response conferred by 
the mineral oil emulsion vaccinated group.  Groups receiving only one subcutaneous 
administration demonstrated partial protection, exhibiting 56-64% survival after 
challenge, depending on the group.  Groups receiving only oral administration of the 
complex did not acquire any protective immunity against the HPAI challenge and 0% 
survival was observed. As expected, no survival was obtained in the sham vaccinated 
control group. 
 
Table 2.  HPAI-loaded adjuvant complex challenge trial treatment groups and 
survival data.   
Birds were immunized with the guided-complex loaded with Egret/02 H5N1 HPAI virus 
either subcutaneously (S.C.) or orally.  Prime occurred at 14 days of age and boosts were 
administered at 28 days of age.  A group received iAIV without adjuvant to serve as a 
comparison.  Another control group received an oil emulsion based vaccine 
subcutaneously at Day 10 without boost.  Birds were challenged at 35 days of age with 
homologous AIV.  Percent survival was calculated at 4 days post-challenge. 
Prime  
(Day 14) Route 
Boost  
(Day 28) Route 
Challenge 
(Day 35) 
% Survival 
(Day 40) 
-- -- -- -- No 100 
-- -- -- -- Yes 0 
Oil Emulsion S.C. -- -- Yes 100 
iAIV S.C. iAIV S.C. Yes 36 
Complex S.C. Complex S.C. Yes 100 
Complex S.C. Complex Oral Yes 56 
Complex Oral Complex Oral Yes 0 
Complex S.C. -- -- Yes 64 
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Discussion 
 With these data, the antibody-guided complex has been successfully used to 
present whole virus, beyond its initial testing with short, synthetic peptides.  The M2e 
region was targeted as a method to load the virus onto the complex, but the immune 
response was evaluated by HI assays, which primarily measures neutralizing antibodies 
against the viral hemagglutinin.  Use of anti-M2e antibody to load the virus onto the 
complex did not diminish antibody production against HA, but enhanced the speed of 
the immune response, and potentially also its duration, as the virus was guided to the 
CD40 receptor using this complex.  Interestingly, neutralizing antibody titers were still 
detected six weeks after a single prime injection.  Previous immunogenicity studies had 
not measured sustained response beyond a couple weeks post-immunization (88).  The 
data presented not only prove this delivery method is capable of inducing a sustained 
antibody response, but also that the antibodies maintain their functionality and are still 
capable of neutralizing virus.  This method was also able to match efficacy, based on 
survival, of a traditional oil emulsion-based AI vaccine produced by the company and is 
the first study to confirm protective efficacy using the antibody-guided complex in 
poultry, specifically against HPAI. 
 Many adjuvant studies have been completed in an effort to enhance AI vaccine 
immunogenicity and efficacy beyond the standard mineral oil emulsion formulation, 
either by expressing HA proteins on a recombinant vector (119), by the addition of 
immunopotentiators to the formulation (120), or switching to a DNA vaccine platform 
(121).  These studies have reported varying results, ranging from only slightly increased 
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immunogenicity, to reduction of viral shedding, and from partial to full protection, but 
none of these vaccine candidates have been implemented as a replacement to mineral oil 
emulsion based AI vaccines.  As a potential vaccine component against HPAI, this 
antibody-guided adjuvant has proven to dramatically enhance both immunogenicity and 
protection of inactivated virus.  Because the complex was developed using anti-M2e 
antibodies, a conserved region on all Type A AI viruses, the modified complex can be 
mass-produced and stockpiled prior to use, to then be mixed with crude allantoic fluid 
containing any inactivated AI virus prior to vaccine administration.  The complex used 
in this study was tested with both LPAI and HPAI viruses, both of which demonstrated 
highly positive immune responses (immunogenicity measured by HI titer and/or 
protection against challenge).  In countries that only allow the use of vaccination as an 
emergency program in the event of a highly pathogenic AI outbreak, induction of a rapid 
immune response is necessary to prevent mortality and the guided adjuvant complex 
accommodates this need.  In countries with endemic AI implementing a vaccination 
program, the addition of the antibody-guided complex to the existing vaccine 
formulations or to replace the initial priming immunization would allow for enhanced 
immunogenic efficacy and reduced induction time.   
In its current incarnation, use of this system would not be economically feasible 
for general poultry vaccination programs because it is too costly to produce, with AI as 
its target or otherwise.  Further research using the antibody-guided complex needs to be 
completed in order to optimize the administration route to accommodate ease of use 
within the poultry industry.  Subcutaneous immunizations require individual bird 
  49 
handling and experienced personnel to administer the vaccine, which is cost-prohibitive 
for the industry (although it is not an unusual practice in low wage developing 
countries).  If formulated as a stable feed additive or spray while maintaining efficacy, 
the guided complex would become more accessible for the industry.  This would require 
optimization to a more efficient and stable version for oral or mucosal delivery.  Dosage 
studies will also need to be completed in order to reduce the amount of complex and 
inactivated virus needed while maintaining efficacy.  Reducing cost per dose would be 
an important factor for an industry that maintains billions of birds.  Time course studies 
will also need to be performed to monitor lasting protection beyond initial immunization.  
The present study monitored antibody titers up to six weeks after a single injection, but 
the extent of time the birds are protected beyond this period would be a very important 
consideration to gauge effectiveness and to schedule a booster immunization program in 
longer-living birds, such as layers or breeders.  Converting from a monoclonal antibody 
system to a recombinant expression system would also be advantageous during 
production and consequently make each dose less expensive after initial set-up.  
Recombinant production is easier to scale up for mass production (e.g. in a plant 
expression system) and allows more control over design/manipulation and quality 
assurance testing.  This would potentially allow all components used in this design (4 
antibodies incorporated onto a streptavidin scaffold) to be expressed as one single entity, 
reducing preparation steps and time, and therefore potential mistakes, currently required 
to formulate the adjuvant complex before use.  Degree of cellular immunity involvement 
has also yet to be confirmed using this system in chickens; however, it can be reasonably 
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assumed that helper T-cell responses are stimulated because this is required for 
downstream recurrent B-cell activation, class switching and affinity maturation 
responses.  The extent of cytotoxic T-cell involvement remains unknown.  Although in 
its current form this vaccine adjuvant system requires optimization of production and 
administration regimen, this system may nevertheless be cost effective, even in the 
United States, to protect high value animals, such as breeder stocks.  
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CHAPTER IV   
DEVELOPMENT OF MONOCLONAL ANTIBODIES AGAINST DENDRITIC CELL 
MARKER CD205 AND ITS USE TO ISOLATE DENDRITIC CELLS FROM 
PERITONEAL EXUDATE CELLS 
 
Introduction  
Dendritic cells serve as the primary antigen-presenting cell for the immune 
system, the only professional APC capable of initiating activation of T-cells for 
downstream adaptive immune responses (122).  In order to obtain chicken DCs, current 
protocols require the isolation of bone marrow myeloid progenitor cells and the 
induction of dendritic cell differentiation by the supplementation of GM-CSF and IL-4 
cytokine growth factors into the cell culture (70).  Maturation of these cells is performed 
completely within in vitro settings, which may not be fully representative of the in vivo 
environment nor the naturally maturing host DCs itself.  A verified, standard isolation 
method to recover fully matured dendritic cells from chickens has yet to be employed by 
the poultry research field.   
Reagent development for DC-specific research is also limited in chickens. 
Because of the challenges with providing a native cell for screening purposes, 
development of monoclonal antibodies against chicken DCs has been difficult.  The 
CD205 receptor is a large surface receptor that serves as a dendritic cell marker and a 
potential target for antibody development (123).  CD205, previously designated DEC205 
or Lys75, is a mannose receptor expressed primarily on cortical thymic epithelial cells 
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and dendritic cells in mice (66).  In the chicken, this 1732 amino acid/199.62 kDa 
protein contains one ricin B-type lectin domain at its N-terminus, followed by ten C-type 
lectin-like domains, and is trailed by a transmembrane anchoring domain (Figure 11) 
(69).  Recombinant expression of the protein has also proven problematic due to the 
protein’s large size, profuse glycosylation sites, and numerous repeat regions.  Recently, 
monoclonal antibodies against chicken CD205 were developed by targeting specific C-
type lectin domains at the center of the protein (70), bypassing use of the whole protein.  
 
 
 
Figure 11.  Diagram of CD205 domains. 
CD205 contains a ricin B-type lectin at its N-terminus and is followed by ten C-type 
lectin (CLECT) binding domans and is trailed by a transmembrane anchoring domain 
(indicated by a blue block).  Domain prediction analysis and diagram obtained from 
ExPASy protein analysis resources (124). 
 
 
Chicken peritoneal exudate cells (PEC) have traditionally been a source of 
various immune cells for ex vivo studies, primarily to isolate heterophils and 
macrophages (125).  In this study, we observe the presence of dendritic cells within the 
PEC population and propose this cell collection method as an alternative method to 
isolate and study chicken primary, mature DCs.  Concurrent experiments were 
performed on PECs to develop monoclonal antibodies against the CD205 receptor and 
were successfully used to isolate CD205+ cells from PECs, further expanding the 
reagents available for chicken DC research. 
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Materials and Methods 
Antibodies utilized 
Anti-chicken MHCII and Bu-1 monoclonal antibodies used for 
immunofluorescent assay (IFA) staining were obtained commercially and used to stain 
all APCs or B-cells, respectively (Southern Biotech, Birmingham, AL).  Anti-CD40 
antibody was a non-commercial monoclonal antibody developed in the Berghman lab 
and used as a second marker for all professional APCs during IFA staining (87).  The 
anti-CD205 antibodies used were developed in this study and not commercially 
obtained.  Secondary antibodies, non-specific mouse IgG antibodies used for blocking, 
and streptavidin conjugates were obtained from Jackson Immunoresearch (West Grove, 
PA).  Anti-histadine (His) tag monoclonal antibodies were used to verify recombinant 
CD205 protein expression and purification (Thermo Scientific, Rockford, IL). 
 
Collection and culture of peritoneal exudate cells (PEC)   
Spent hens were injected intraperitoneally with 8 ml of 3% (w/v) Sephadex G50 
(Sigma-Aldrich, St. Louis, MO) in sterile PBS.  After 42 hours, birds were euthanized by 
CO2 asphyxiation and a small incision was made into the abdomen.  The peritoneal 
cavity was flushed with 35 ml of PBS to recover peritoneal exudate cells.  Initial 
collection sample was centrifuged to pellet down cells and then washed once with PBS.  
The cell pellet was resuspended in PBS and mononuclear cells purified using 
Histopaque-1077 (Sigma-Aldrich) following manufacturer instructions.  Mononuclear 
cells recovered after density gradient separation were used as a source of PECs in 
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following experiments.  Initial studies removed macrophages by plastic adherence.  This 
was completed by culturing the PECs in tissue culture treated flasks in Roswell Park 
Memorial Institute (RPMI) medium supplemented with 5% (v/v) chicken serum, 8% 
(v/v) fetal bovine serum (FBS), 1mM sodium-pyruvate, 2mM L-alanyl-L-glutamine, 100 
units/ml penicillin, and 100ug/ml streptomycin for 4 hours.  Cells attached to the flask 
were considered adherent (Ad) PECs and cells remaining in suspension were considered 
non-adherent (Non-Ad) PECs.  Subsequent flow cytometry and morphological studies 
utilized affinity-purified CD205+ cells using the developed monoclonal antibodies, 
omitting plastic-adherence separation.  Peripheral blood mononuclear cells (PBMC) and 
spleen mononuclear cells were also collected by Histopaque-1077 polysucrose gradient 
and used as control samples for comparison.   
 
Generation of anti-chicken CD205 monoclonal antibodies   
Previous development of anti-CD205 monoclonal antibodies by Wu et al. 
targeted the C-type lectin domains 4-6.  The nucleotide sequence for C-type lectin 
domains 4-6 was obtained from NCBI gene databases and codon optimized for bacterial 
protein expression.  The redesigned, truncated chicken CD205 gene was synthesized into 
a pUC57 cloning vector by a commercial vendor (Genscript, Piscataway, NJ).  The gene 
synthesis product was used for cloning and expression of the truncated CD205 protein 
by transformation into BL21 Star E. coli of the Invitrogen Champion TOPO cloning 
system (Life Technologies, Grand Island, NY).  Protein expression was induced using 
1mM isopropyl β-D-1-thiogalactopyranoside when bacterial culture reached an OD600 of 
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0.5-0.8.  After 6 hours, bacterial cultures were washed five times with PBS and bacterial 
pellets were frozen at -20°C to aid in cell wall lysis.  B-PER Bacterial Protein Extraction 
Reagent (Thermo Scientific) was used to extract bacterial protein from the cytoplasm, 
and recombinant CD205 protein was purified from the extract using Nickel-NTA affinity 
chromatography.  Full-length expression was verified by western blot against the C-
terminal His-tag marker.  Purified recombinant chicken CD205 was quantified by 
Bradford assay and was used as the immunogen for monoclonal antibody development 
or as coating protein for screening ELISAs. 
Female Balb/c mice (Charles Rivers, USA) were subcutaneously immunized 
with 50 µg of recombinant chicken CD205 (C-type lectin domains 4-6) protein per 
mouse in RIBI buffer.  Three subcutaneous boosts with 25 µg/mouse were performed at 
three-week intervals.  Plasma was collected 1 week after each immunization to monitor 
the specific IgG response against the recombinant CD205 protein based on ELISA and 
western blot.  Once mice were hyper-immunized, based on the antibody titer plateaus, 
mice were sacrificed and splenocytes harvested.  Splenocytes were used for 
electrofusion with mouse Sp2/0 myeloma cells to produce B-cell hybridomas using an 
Electro Cell Manipulator ECM 2001 (BTX, Holliston, MA).  Hybridoma cultures were 
maintained at 37°C at 5% CO2 and cultured in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 15% (v/v) FBS (Atlanta Biologicals, Lawrenceville, GA).  
Hybridoma supernatants were screened for CD205-specific antibody production via 
ELISA against recombinant CD205 protein and immunofluorescence assays against non-
adherent peritoneal exudate cells.  Based on these criteria, parent hybridomas were 
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chosen, and subsequently sub-cloned by limiting dilution.  Sub-cloned hybridomas were 
screened again following the same methods before the final monoclonal sub-clones were 
selected for ascites production (Antagene, Santa Clara, CA) and cryogenic storage.  
Antibodies were purified from ascites using Protein G affinity columns (Thermo 
Scientific) following manufacturer instructions.  For downstream flow cytometry or 
magnetic sorting applications, the anti-CD205 antibodies were biotinylated using EZ-
Link Sulfo-NHS-LC-Biotin (Thermo Scientific) following manufacturer provided 
procedures. 
 
Flow cytometric analysis of CD205+ cells from PEC   
Anti-CD205 monoclonal antibodies were used to estimate DC percentage in 
chicken blood and spleen cell populations via flow cytometric analysis.  Cells were 
collected from birds 1 week after vaccination with commercial Newcastle’s Disease 
Virus vaccine to ensure activation of the immune system.  Cells were washed with 
fluorescence-activated cell sorting (FACS) buffer (PBS supplemented with 5% FBS and 
0.1% (w/v) sodium azide) and aliquoted to 1x106 cells portions.  Cell surface Fc 
receptors were be blocked by incubation with 1µg of unlabeled mouse IgG for 15 
minutes at 4°C prior to staining.  Primary incubation with biotinylated mouse anti-
chicken CD205 monoclonal antibodies was performed for 1 hour at 4°C.  Washes were 
performed with 0.5mL FACS buffer.  Secondary incubation occurred with streptavidin-
Pacific Blue conjugate.  Cells were fixed with 2% paraformaldehyde in PBS and filtered 
through 40µm cell strainers to ensure single-cell suspension.  Flow cytometric analysis 
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was performed using the BD FACSAriaII System (BD Biosciences, San Jose, CA) at the 
TAMHSC College of Medicine - Cell Analysis Facility and data were analyzed using 
FlowJo software.   
 
Magnetic-sorting and culture of CD205+ cells from PEC.   
A 50%-50% mix of two anti-CD205 monoclonal antibodies, designated 3B6-2B1 
and 2F1-1G3 was biotinylated and used to functionalize streptavidin-coated magnetic 
beads (BioLegend, San Diego, CA).  After collection of PECs, the anti-CD205 
functionalized beads were mixed with PECs at a ratio of 100µl of beads to 1x108 cells 
and incubated on ice for 30 minutes.  Cell isolation procedures followed the 
manufacturer’s recommendations.  CD205+ sorted cells were further cultured in growth 
media supplemented with 50ng/mL each of GM-CSF and IL-4 growth factors 
(Kingfisher Biotech, St. Paul, MN).  Cells were cultured for 48 hours before activation 
using 1µg/ml lipopolysaccharide (LPS) from Salmonella enterica serotype enteritidis 
(Sigma-Aldrich).  
 
 Live animal work and permits.   
Mouse and bird handling procedures were performed under animal use permit 
#2013-0254.  Mice were obtained from Charles Rivers Laboratories and general care 
provided through the College of Veterinary Medicine Comparative Medicine Program. 
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Results 
Presence of dendritic cells observed in PECs 
Initial observation of PECs after removal of highly adherent macrophages by 
plastic adherence indicated APCs remained in the non-adherent population based on IFA 
staining against MHC-II (Figure 12).  This population of cells was also stained with anti-
Bu-1 (a B-cell marker) and anti-CD40 (marker for all APCs).  Staining for Bu1 showed 
fewer immunopositive cells than revealed with general APC markers (anti-MHC-II and 
anti-CD40).  Since the majority of the macrophages have been removed by plastic 
adherence, the difference in staining could theoretically be explained by the presence of 
dendritic cells.  Once the Non-Ad population was activated with LPS for 24 hours, the 
CD40-positive staining cells increased in frequency and intensity within this Non-Ad 
PEC population (Figure 12).  Total RNA was extracted from Ad and Non-Ad PEC 
populations and further reverse-transcribed to complementary DNA (cDNA) to measure 
the gene expression of the CD205 receptor, using glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as the house-keeping control gene.  Amplification of CD205 
receptor cDNA can be seen on the resulting gel electrophoresis of the polymerase chain 
reaction (PCR) product at the theoretically expected length of 299 bases in the Non-Ad 
PEC population (Figure 13), but not in the Ad population.  Results strongly suggested 
that CD205+ DCs were/are a subset of the Non-Ad cell population and confirmed that 
peritoneal exudate cell collection might indeed be a feasible method to obtain primary 
DCs. 
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Figure 12.  Immunofluorescent staining of non-adherent PECs with APC marker 
antibodies.   
Adherent PECs removed by plastic adherence and non-adherent cells fluorescein 
isothiocyanate (FITC)-stained (green) against A) MHC-II, B) Bu-1, C) CD40, and D) 
CD40 after activation with LPS for 24 hours.  Nuclear DNA was stained with 4',6-
diamidino-2-phenylindole (DAPI) (seen in blue) in all images. 
 
A B 
D C 
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Figure 13.  Expression of CD205 mRNA in non-adherent PECs but not in adherent 
PECs.   
 
 
Anti-CD205 monoclonal antibodies stain PECs   
After presence of CD205+ cells was confirmed, a truncated version of the CD205 
protein receptor was designed for recombinant protein expression, specifically to be used 
as a target immunogen for monoclonal antibody development.  Only C-type lectin 
domains 4-6 were used for protein expression in Escherichia coli, following the initial 
design as described by Wu et al. (2010) to avoid previous whole CD205 protein 
expression issues.  This recombinant, truncated version contained a C-terminal His-tag 
marker and the identity of the resulting protein was verified by western blot (Figure 14).  
This protein preparation with an estimated purity of approximately 85% was used at to 
immunize and screen mice for anti-CD205 monoclonal antibody development.  
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Resulting subcloned monoclonal hybridomas were screened for anti-CD205 antibody 
production by IFA on Non-Ad PECs.  Results for three of the positive monoclonal 
candidates are shown in Figure 15, all of which stained a subpopulation of the Non-Ad 
PECs.  Further applications of the monoclonal antibodies, including flow cytometry or 
magnetic bead cell sorting, used monoclonals 3B6-2B1 and 2F1-1G3, either alone or in a 
mixed manner.    
 
 
Figure 14.  Truncated CD205 protein expressed in E. coli system based on His-tag 
staining.   
Anti-His-tag stained western blot after Ni-NTA purification of the protein.      
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Figure 15.  Screening of different candidate monoclonal antibodies against CD205 
on non-adherent PECs. 
Non-Ad PECs screened for anti-CD205 staining (green) with three different candidate 
hybridomas A) 3B6-2B1, B) 2F1-1G3, and C) 2F3-1D6.  Nuclear DNA was stained blue 
with DAPI in blue. 
A 
B 
C 
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Percentage of CD205+ DCs in PECs 
Purified monoclonal antibodies against CD205 receptor were biotinylated and 
used with a streptavidin-conjugated Pacific Blue fluorophore for flow cytometry 
screening.  Spleen and blood samples were collected (one week after vaccination with a 
commercially available Newcastle’s Disease Virus vaccine to ensure immune response 
activation) for analysis of CD205+ staining cells.  Mononuclear cells were collected from 
each sample type and stained with individual monoclonal antibody candidates, 3B6-2B1 
or 2F1-1G3.  Resulting CD205+ staining percentage of the mononuclear cells ranged 
from 6.7-9.8% (Table 3).  As dendritic cells typically range from 5-10% of the immune 
cells (126), these data correlate with previously described DC literature.  PECs were not 
analyzed by flow cytometry as the cell population is naturally sticky when collected 
from the peritoneal cavity and prone to clogging the flow cell during flow cytometric 
analyses.  Magnetic purification of CD205+ cells was performed by binding biotinylated 
anti-CD205 antibodies to streptavidin-coated magnetic beads.  A 50%-50% mix of both 
monoclonal antibodies was used to functionalize the magnetic beads.  This procedure 
was performed on spleen mononuclear cells and PEC samples, recovering 7.15x106 and 
2.15x107 cells from each respective source (Table 4).   
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Table 3.  Flow cytometry using anti-CD205 mAb on spleen and PBMC samples. 
Birds were vaccinated with commercial Newcastle’s Disease Virus to activate the 
immune system.  Spleen mononuclear cells and PBMCs were stained using anti-CD205 
monoclonal antibodies and percent stained were analyzed by flow cytometry. 
Source (age) 
CD205+ 
(3B6) 
CD205+ 
(2F1) 
Spleen (Day 7) 7.2% 9.8% 
Blood (Day 7) 8.7% 6.4% 
Spleen (Day 24) 6.7% 6.8% 
 
 
Table 4.  Magnetic sorting of CD205+ cells.   
Monoclonal anti-CD205 antibodies were mixed 50%-50% and loaded onto magnetic 
beads and used to sort CD205+ cells from spleen mononuclear cells or PECs. 
Source 
Starting Total 
# Cells 
CD205+ 
Purified 
% CD205+ 
Purified 
Spleen 1x109 7.15x106 7.15% 
PECs 1.5x108 2.15x107 19.4% 
 
 
Morphology of cultured PEC-DCs   
Initial isolation of CD205+ cells from PECs exhibit no morphological differences 
post-purification procedure (Figure 16), but observation of PECs after activation show 
distinct development of appendages, or arms, in cultures of both whole PECs (Figure 17) 
and CD205+ sorted PECs (Figure 18).  Culture of PECs itself seems to induce low levels 
of activation based on slight arm development (Figure 17), while the sorting procedure 
induces a greater level of activation (Figure 18).  These background activation responses 
do not reach the superior levels of appendage development and cellular aggregation 
induced by LPS activation.  Additionally, immunofluorescent staining of sorted and 
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activated PECs against CD40 and CD205 show positive expression of both receptors 
(Figure 19).  In contrast, CD205+ isolated cells from spleen exhibit low reactivity after 
the sorting procedure and only slight appendage development after LPS activation 
(Figure 20).  These cells also do no engulf or clear the magnetic beads bound to the 
cellular surface during the isolation procedure as efficiently as PEC-derived cells once 
placed in culture. 
 
 
 
Figure 16.  Crude vs. CD205+ sorted PECs.  
PECs A) before and B) after sorting by magnetic isolation for CD205+ cells using the 
monoclonal antibodies. 
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Figure 17.  Unsorted PECs cultured and LPS-activated/stimulated.   
Crude, unsorted PECs were cultured with growth factors for 48 hours and then left A) 
non-activated or B) activated with 1µg/ml LPS for 48 hours. 
 
 
 
Figure 18.  PECs sorted for CD205+ cells cultured and activated.   
CD205+ PECs cultured for 48 hours with growth factors and left A) non-activated or B) 
activated with 1µg/ml LPS for 48 hours. 
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Figure 19.  Immunofluorescent staining of CD205+ sorted and activated PECs 
against APC markers.   
Sorted CD205+ PECs stained against A) CD40 or B) CD205. 
 
 
 
Figure 20.  CD205+ sorted spleen cells.   
Sorted splenocytes were cultured with growth factors for 48 hours before cells were left 
A) non-activated or B) activated by 1µg/ml LPS. 
 
 
Discussion 
Based on this study, peritoneal exudate cells are a viable source for primary 
mature dendritic cells from chickens.  These dendritic cells can be recovered from the 
bird fully matured or placed into culture for further activation and manipulation.  The 
A B 
A B 
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PEC collection method requires less labor than bone marrow myeloid progenitor 
collection, as well as less time in culture before use since mature DCs are already in the 
recovered PEC population and do not require additional differentiation.  These cells also 
exhibit normal branched projection/dendrite, development and cellular aggregation upon 
activation stimulus, indicative of the dendritic cell response (126).  Isolation of CD205+ 
cells from PECs by magnetic sorting produced a higher percentage of recovered cells 
compared to splenic origin.  In theory, a higher percentage of DC recovery could be 
expected from PEC, as this population of cells was specifically activated for induced 
migration of immune cells into the area of interest, while the spleen houses multiple 
immune cells awaiting activation upon influx of circulating lymph which skews the 
starting populations before purification.  Monoclonal antibodies were also generated 
against the chicken CD205 receptor, the first to be reported in the United States.  These 
antibodies were successfully used in multiple applications, including ELISA, western 
blot, immunofluorescence, flow cytometry, and magnetic bead purification for 
downstream cell culture.   
Targeting CD205 is known to initiate downstream induction of type II MHC 
antigen presentation and type I MHC antigen cross-presentation (65, 67, 127, 128).  
Induction of both MHC antigen presentation pathways allows for the subsequent 
activation of both CD4+ and CD8+ T-cells, respectively (122).  Theoretically, targeted 
activation of a dendritic cells with a specified immune target should induce a stronger 
and more rapid immune response in comparison to traditional unguided immunization 
methods that require longer induction times (129).  Murine studies have also indicated 
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targeting CD205 during immunization is capable of inducing an even stronger immune 
response than CD40-targeting, while decreasing the required antigen load (130, 131).  
This research has yet to be completed in avian systems as DCs are the least characterized 
immune cell within the chicken, but may be the next step in characterizing the anti-
CD205 antibodies developed.  Antigen presentation and subsequent immune 
mechanisms induced by CD205 receptor activation also differ from CD40 downstream 
responses, thus targeting of one specific receptor may be better than another depending 
of the pathogen’s mode of infection. Combining CD40 and CD205-targeting within the 
same vaccine would also be an option, increasing coverage of different antigen-
presentation pathways and downstream responses, therefore ensuring chances for 
inducing protection.   
Further analysis of the PEC-sourced primary dendritic cells is necessary to 
understand where these DCs originate before migration into the peritoneal cavity.  
Functional characterization and comparison to bone marrow origin DCs would also be of 
interest.  Different subsets of DCs perform different roles, and therefore vary in immune 
response (65, 132).  This is particularly important to distinguish, as certain assays may 
be more suited to a specific source, and therefore subset, of DC.  Analysis of the 
monoclonal antibodies developed in this study also requires additional research.  Beyond 
its use to bind and purify CD205+ cells, these antibodies have not been tested to confirm 
whether they possess antagonistic functions, agonistic functions, purely recognize and 
bind the receptor, or induce development of immune tolerance.  Published literature 
targeting CD205 in murine models has induced both pro-inflammatory and anti-
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inflammatory effects, but a consensus has yet to be reached on the controlled effects 
from targeting dendritic cells (67, 133, 134).  Despite the additional research required to 
further characterize the PEC-sourced DCs and anti-CD205 antibodies, the report of both 
has provided an additional resource of reagents for research and development in 
chickens. 
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CHAPTER V  
CONCLUSIONS 
 
 The use of antibody-guided complexes in poultry is still relatively new, and its 
prospective applications still being discovered.  The work presented herein was able to 
further extend the use of guided-complexes, primarily as a technique for rapid polyclonal 
sera production in chickens and as a potential epitope mapping method for target 
identification of microbial toxins.  These data have also advanced the potential of 
antibody-guided complexes as vaccine adjuvant platforms.  With the AIV 
immunogenicity and efficacy trials, this research is the first to report successful 
adaptation and application of the guided complex with whole pathogen instead of a 
synthetic peptide, measure fast and long-lived functional antibody responses up to six 
weeks after a single immunization, and the first reported study to transition from 
immunogenicity data to protective efficacy using the guided-complex system in poultry. 
Now that efficacy has been reported using the antibody-guided system in poultry, 
optimization is the next step to making the system more efficacious and implementable 
for the poultry industry.  Antibody-guided complexes are more expensive and 
complicated to produce than traditional vaccines and development of a less expensive 
complex, and perhaps a recombinant bi-specific single-chain protein, would be more 
cost effective and user-friendly for the industry.  A unified, single complex would not 
require preliminary processing and manipulation, which would also decrease the 
probability of errors during manufacturing.  Administration through feed or spray 
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immunization is also favored by the industry, as those methods do not require handling 
of individual birds by trained personnel.  Studies to increase efficacy of mucosally-
administered complex would be a reasonable next step and its successful production 
would clear a major obstacle hindering introduction to mass application.  Our completed 
studies currently described protocols with the priming administration at two weeks of 
age to avoid interference by maternal antibodies, but broilers only live to 6-7 weeks 
before processing once the target weight has been achieved and require established 
protection against disease immediately after maternal antibodies naturally degrade from 
their systems.  Despite establishing a response within a matter of days, the current 
guided-complex vaccination timeline leaves the bird vulnerable to infection during this 
gap in time, after maternal antibodies diminish and before vaccine-induced protection is 
conferred.  Vaccination in ovo or at day-of-hatch to provide protection at an earlier age, 
preferably without requiring a boost, would be more relevant for this industry and 
presents another opportunity for further research.  Proper targeting and manipulation of 
the immune response will also need to be addressed in in vivo antigen targeting research.  
Although there are many murine and human studies which report successful induction of 
pro-inflammatory immune responses when targeting the CD40 receptor, studies with 
conflicting results have also been described.  Some studies assert CD40-targeting is 
sufficient to induce memory T-cell development (135), while other studies claim CD40-
targeting is only able to induce CD8+ cytotoxic effector T-cells without further 
development of memory T-cells (136).  Thus, studies of the CD40-targeting system’s 
ability to induce cytotoxic T-cells and T-cell memory will also need to be conducted in 
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poultry to confirm inducible T-cell involvement.  Additionally, the information gathered 
from these studies would help elucidate and confirm T-cell effector and memory 
induction mechanisms for avian immunologists in general. 
Our studies also report the introduction of additional reagents that will advance 
the field of poultry immunology research, namely with the development of anti-CD205 
receptor monoclonal antibodies and a novel technique to obtain primary mature DCs.  
With these new reagents, further research and characterization of the anti-CD205 
antibodies as well as the isolated PEC-DC population can be initiated.  It would be 
interesting to discern what type of function the anti-CD205 antibodies possess, such as 
whether these antibodies merely bind or whether they are able to neutralize or activate 
their targeted DCs.  This study could be completed by collecting bone marrow derived 
DCs to use as a naïve population and in vitro testing of the cellular functions after 
application of the antibody.  Beyond being a primary antibody for use in laboratory 
assays, the ideal utilization of the anti-CD205 antibodies would be its inclusion in the 
antibody-targeting systems to present antigen directly to DCs.  With this in mind, some 
challenges will be faced when using CD205-targeting.  Manipulation of the immune 
response by targeting CD205 has shown to be more complicated than CD40 targeting.  
Engagement of the CD40 receptor provides the co-stimulation needed to provoke APC 
activation, a single pathway with many outcomes, but all within the same scope of pro-
inflammatory response.  In contrast, DCs control all downstream responses to antigens 
by stimulating naïve T-cells to differentiate into different helper subsets, ultimately 
resulting in either activating or tolerizing environments.  Because DCs initiate and 
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dictate the appropriate immune response during antigen presentation and activation of 
lymphocytes, controlled manipulation of DCs reactions is more difficult to predict and 
regulate.  This further emphasizes the need to conduct studies using the recently 
developed anti-CD205 antibodies to test their ability to activate and induce 
immunogenic responses against specific antigens.  For preliminary in vivo trials, this can 
be accomplished by using the established system of loading synthetic peptide onto a 
CD205-targeting complex and testing for inducible antigen-specific immunogenicity.  
CD205+ DCs are also capable of presenting antigen on both MHC-I and MHC-II 
complex (64, 65), and targeting these cells has become very desirable to scientists who 
want to specifically stimulate CD8+ cytotoxic T-cell responses, particularly against 
diseases which cannot be controlled by humoral immune response with high neutralizing 
antibody levels.  Unfortunately, to direct antigen towards a particular antigen 
presentation context, it is not sufficient to simply conjugate the antigen onto a CD205-
targeting antibody.  Studies have discovered that CD205+ receptor expression levels, 
speed of internalization, as well as amount of delivered antigen during CD205-targeting 
all govern preferential presentation on MHC-I or MHC-II (131).  Research will need to 
be conducted to identify the specific requirements to control preferential presentation of 
antigen in the context of specific MHC complexes, a study which would help explain the 
mechanism for those attempting to manipulate this system and clarify the system to the 
field immunology of.  DCs also determine if the eventual outcome of antigen-
presentation will be either immunity or tolerance, a mechanism that is currently not fully 
understood and thus cannot be efficiently manipulated until more knowledge is 
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generated on this subject (75, 137).  Antigen conjugated to anti-CD205 antibodies has 
been able to induce CD8+ cytotoxic T-cell activation (138), but CD205+ DCs have also 
been described to prompt development of Foxp3+ regulatory T-cells (139).  In addition, 
some studies state that targeting CD205 per se is sufficient to induce an immune 
response, while others state that solely targeting CD205 induces tolerance (140).  Most 
studies seem to agree that combined targeting of both CD40 and CD205 can overcome 
tolerization responses and push the DC response towards immune cell activation (141).  
This data suggest that future anti-CD205 targeting investigations should be completed 
alongside anti-CD40 targeting to confirm whether the combination of the two targeting 
systems is able to provoke increased immunogenicity compared to singular CD205 or 
CD40-targeting administration, with perhaps even a synergistic effect when used in 
combination.  Whether the desired goal is to induce activation or tolerance, the exact 
mechanism to fine-tune targeted control of the immune response using antibody-guided 
approach has yet to be clearly defined, providing opportunities for future researchers to 
uncover the many facets involved in avian immunological manipulation. 
The research presented in this dissertation has substantially contributed to the 
development of antibody-guided complexes for poultry use by 1) introducing the use of 
the guided system for epitope mapping of microbial enzymes, 2) providing proof of 
principle for loading whole pathogen onto the complex, 3) proving protective efficacy 
against a high profile disease, and 4) developing new anti-CD205 antibodies to 
specifically target DCs while also presenting another method to isolate DCs from 
chickens.  Although it is also clear that the current prototype is far from perfect, this 
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research has significantly assisted with the advancement of the antibody-guided systems 
in poultry.  Literature clearly demonstrates antibody-guided immunization is more 
nuanced and convoluted than originally assumed and considerable research efforts are 
still necessary to elucidate the critical elements in immune response manipulation with 
antibody-guided complexes, but the prospective applications are vast and worth the 
effort both in terms of unveiling further basic scientific knowledge of the immune 
response and in terms of offering novel resources for applied veterinary or biomedical 
use.   
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